Drug Trial Radar · NCT06637423
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Dec 20, 2024
Primary completion
Sep 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.
Conditions
- Non-Muscle Invasive Bladder Cancer
Interventions
Sacituzumab tirumotecanDrug
Intravesical administration
Rescue medicationDrug
Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
Supportive care measuresDrug
Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose Limiting Toxicity (DLT)Time frame: Up to approximately 7 weeks
- Number of Participants Experiencing an Adverse Event (AE)Time frame: Up to approximately 10 weeks
- Number of Participants Discontinuing Study Treatment due to an Adverse Event (AE)Time frame: Up to approximately 6 weeks
Locations
13 sites in 6 countries. Site status is shown where the registry gives one.
Michael G Oefelein Clinical Trials ( Site 0053)
Bakersfield, California
Moffitt Cancer Center ( Site 0057)
Tampa, Florida
Northwestern University ( Site 0051)
Chicago, Illinois
Johns Hopkins University ( Site 0055)
Baltimore, Maryland
Princess Margaret Cancer Centre ( Site 0003)
Toronto, Ontario, Canada
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0002)
Sherbrooke, Quebec, Canada
Hôpital Claude Huriez ( Site 0012)
Lille, Nord, France
HENRI MONDOR HOSPITAL ( Site 0011)
Créteil, Val-de-Marne, France
Gustave Roussy ( Site 0013)
Villejuif, Val-de-Marne, France
Erasmus Medisch Centrum ( Site 0032)
Rotterdam, South Holland, Netherlands
Hospital Universitario 12 de Octubre ( Site 0042)
Madrid, Spain
Hospital Universitario Virgen de la Victoria ( Site 0043)
Málaga, Andalusia, Spain
St Bartholomew s Hospital ( Site 0061)
London, London, City of, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.